Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder

• Status: Completed
• Trial end date: 2006-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will test the efficacy, safety and tolerability of XBD173 in the treatment of generalized anxiety disorder in patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals

Criteria

Inclusion Criteria:

• Current doctor's diagnosis of generalized anxiety disorder

• In need of psychiatric treatment

• Willingness to complete all aspects of the study

Exclusion Criteria:

• Current doctor's diagnosis of major depression

• History of schizophrenia or schizoaffective disorders

• Drug dependence within 2 months prior to study start

For detailed information on eligibility, please contact the study center nearest to you (see below), or call 1-862-778-8300, or visit the following website:

www.novartisclinicaltrials.com